InMed Pharmaceuticals (INM) Competitors $3.12 -0.27 (-7.96%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$3.14 +0.02 (+0.64%) As of 02/21/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INM vs. AYTU, CYCN, CELZ, AIM, DWTX, INDP, NLSP, CNSP, NEUP, and ADXNShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Aytu BioPharma (AYTU), Cyclerion Therapeutics (CYCN), Creative Medical Technology (CELZ), AIM ImmunoTech (AIM), Dogwood Therapeutics (DWTX), Indaptus Therapeutics (INDP), NLS Pharmaceutics (NLSP), CNS Pharmaceuticals (CNSP), Neuphoria Therapeutics Inc. - Common Stock (NEUP), and Addex Therapeutics (ADXN). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Aytu BioPharma Cyclerion Therapeutics Creative Medical Technology AIM ImmunoTech Dogwood Therapeutics Indaptus Therapeutics NLS Pharmaceutics CNS Pharmaceuticals Neuphoria Therapeutics Inc. - Common Stock Addex Therapeutics Aytu BioPharma (NASDAQ:AYTU) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk. Does the MarketBeat Community believe in AYTU or INM? Aytu BioPharma received 247 more outperform votes than InMed Pharmaceuticals when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAytu BioPharmaOutperform Votes25567.11% Underperform Votes12532.89% InMed PharmaceuticalsOutperform Votes847.06% Underperform Votes952.94% Which has better earnings and valuation, AYTU or INM? InMed Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAytu BioPharma$81M0.10-$15.84M-$1.45-0.93InMed Pharmaceuticals$4.60M0.82-$7.68M-$13.75-0.23 Does the media favor AYTU or INM? In the previous week, Aytu BioPharma's average media sentiment score of 0.00 beat InMed Pharmaceuticals' score of -0.45 indicating that Aytu BioPharma is being referred to more favorably in the media. Company Overall Sentiment Aytu BioPharma Neutral InMed Pharmaceuticals Neutral Which has more risk and volatility, AYTU or INM? Aytu BioPharma has a beta of -1.45, indicating that its share price is 245% less volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Do institutionals & insiders believe in AYTU or INM? 33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 2.8% of Aytu BioPharma shares are owned by insiders. Comparatively, 1.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is AYTU or INM more profitable? Aytu BioPharma has a net margin of -7.62% compared to InMed Pharmaceuticals' net margin of -163.75%. Aytu BioPharma's return on equity of -19.30% beat InMed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aytu BioPharma-7.62% -19.30% -4.80% InMed Pharmaceuticals -163.75%-90.74%-71.70% SummaryAytu BioPharma beats InMed Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.09M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.235.4725.4719.00Price / Sales0.82306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book0.616.717.644.62Net Income-$7.68M$138.33M$3.18B$245.85M7 Day Performance-1.27%-2.61%-1.99%-2.68%1 Month Performance-22.00%-2.32%-0.42%-2.19%1 Year Performance-61.42%-5.31%16.51%12.84% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals0.4323 of 5 stars$3.12-8.0%N/A-61.3%$4.09M$4.60M-0.2310AYTUAytu BioPharma1.0333 of 5 stars$1.39+0.4%N/A-55.0%$8.52M$81M-1.13160High Trading VolumeCYCNCyclerion Therapeutics0.7851 of 5 stars$3.12+3.0%N/A-1.1%$8.46M$1.62M0.0030CELZCreative Medical Technology0.8967 of 5 stars$4.74+3.3%N/A+28.0%$8.30M$10,000.00-1.255Gap DownHigh Trading VolumeAIMAIM ImmunoTech1.9945 of 5 stars$0.13-6.9%$2.75+2,031.8%-67.1%$8.23M$200,000.00-0.2720High Trading VolumeDWTXDogwood TherapeuticsN/A$6.13-8.6%N/AN/A$8.15MN/A-0.945Gap DownINDPIndaptus Therapeutics3.1124 of 5 stars$0.80+2.1%$8.50+963.8%-52.9%$8.15MN/A-0.476Gap UpNLSPNLS PharmaceuticsN/A$2.26-1.7%N/A+364.1%$8.14MN/A0.006Gap UpCNSPCNS Pharmaceuticals3.4724 of 5 stars$0.14+29.9%$0.50+257.1%-99.5%$8.05MN/A0.005Stock SplitNews CoverageGap UpHigh Trading VolumeNEUPNeuphoria Therapeutics Inc. - Common Stock2.2867 of 5 stars$4.94+7.4%$21.00+325.1%N/A$8.05M$10,000.000.00N/AEarnings ReportADXNAddex Therapeutics2.5252 of 5 stars$7.50+6.2%$30.00+300.3%-25.0%$7.95M$1.83M-22.0430 Related Companies and Tools Related Companies AYTU Alternatives CYCN Alternatives CELZ Alternatives AIM Alternatives DWTX Alternatives INDP Alternatives NLSP Alternatives CNSP Alternatives NEUP Alternatives ADXN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INM Stock Alerts